Bard PowerPort claims: who can file and what to do in Pennsylvania

MDL 3081 (In re: Bard PowerPort) is centralized in the District of Arizona before Chief Judge David G. Campbell. Pennsylvania cases from the Eastern District (Philadelphia), Middle District (Harrisburg/Scranton), and Western District (Pittsburgh) are transferred to Phoenix for coordinated pretrial proceedings. Pennsylvania’s large academic medical center network and substantial cancer patient population contribute meaningfully to MDL 3081 case volume.

Pennsylvania imposes a 2-year statute of limitations for personal injury and product liability claims under 42 Pa. C.S. § 5524. Pennsylvania’s discovery rule tolls the statute until the plaintiff knew or should have known of the injury and its factual cause. The Pennsylvania Supreme Court has applied the discovery rule to medical device cases, making it relevant for PowerPort plaintiffs whose catheter fracture was asymptomatic or discovered incidentally during imaging.

Pennsylvania’s oncology infrastructure includes the Abramson Cancer Center at Penn Medicine (Philadelphia), UPMC Hillman Cancer Center (Pittsburgh — one of the largest cancer centers in the country), Fox Chase Cancer Center (Philadelphia), and Jefferson Health’s Sidney Kimmel Cancer Center. These institutions’ high-volume chemotherapy practices mean large numbers of PowerPort recipients among Pennsylvania cancer patients and a correspondingly significant share of MDL filings.

Key federal venues for Pennsylvania PowerPort plaintiffs include the E.D. Pa. (Philadelphia) and W.D. Pa. (Pittsburgh). Both districts have active medical device litigation dockets and transfer cases to MDL 3081. BD’s Bard Medical division has a longstanding presence supplying Pennsylvania health systems. Philadelphia and Pittsburgh are each major Bard distribution hubs, supporting personal jurisdiction in Pennsylvania courts before and during MDL proceedings.